View in EDS HTML Full Text PDF Full Text

Case Report: Lorlatinib for the treatment of ALK-rearranged poorly differentiated thyroid carcinoma after progression to prior ALK-specific tyrosine-kinase inhibitor.

Saved in:
Bibliographic Details
Title: Case Report: Lorlatinib for the treatment of ALK-rearranged poorly differentiated thyroid carcinoma after progression to prior ALK-specific tyrosine-kinase inhibitor.
Authors: Yaringaño J; Medical Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Hernando J; Department of Medical Oncology, Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Neuroendocrine and Endocrine Tumor Translational Research Program (NET-VHIO), Vall Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., García-Álvarez A; Department of Medical Oncology, Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Neuroendocrine and Endocrine Tumor Translational Research Program (NET-VHIO), Vall Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Iglesias-Felip C; Pathology Department, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Zafón C; Endocrinology Department, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Vivancos A; Cancer Genomics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Roca-Herrera M; Medical Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Pérez-Fernández S; Department of Medical Oncology, Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Neuroendocrine and Endocrine Tumor Translational Research Program (NET-VHIO), Vall Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Martínez-Badal S; Neuroendocrine and Endocrine Tumor Translational Research Program (NET-VHIO), Vall Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Oncology Data Science Group (ODysSey), Vall d'Hebron Institute of Oncology, Barcelona, Spain., Elguero B; Neuroendocrine and Endocrine Tumor Translational Research Program (NET-VHIO), Vall Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Stem Cell and Cancer Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Capdevila J; Department of Medical Oncology, Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Neuroendocrine and Endocrine Tumor Translational Research Program (NET-VHIO), Vall Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Source: Frontiers in oncology [Front Oncol] 2026 Mar 09; Vol. 16, pp. 1802225. Date of Electronic Publication: 2026 Mar 09 (Print Publication: 2026).
Publication Type: Case Reports; Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41878530
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Case Report: Lorlatinib for the treatment of ALK-rearranged poorly differentiated thyroid carcinoma after progression to prior ALK-specific tyrosine-kinase inhibitor.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Yaringaño+J%22">Yaringaño J</searchLink>; Medical Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Hernando+J%22">Hernando J</searchLink>; Department of Medical Oncology, Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Neuroendocrine and Endocrine Tumor Translational Research Program (NET-VHIO), Vall Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22García-Álvarez+A%22">García-Álvarez A</searchLink>; Department of Medical Oncology, Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Neuroendocrine and Endocrine Tumor Translational Research Program (NET-VHIO), Vall Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Iglesias-Felip+C%22">Iglesias-Felip C</searchLink>; Pathology Department, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Zafón+C%22">Zafón C</searchLink>; Endocrinology Department, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Vivancos+A%22">Vivancos A</searchLink>; Cancer Genomics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Roca-Herrera+M%22">Roca-Herrera M</searchLink>; Medical Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Pérez-Fernández+S%22">Pérez-Fernández S</searchLink>; Department of Medical Oncology, Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Neuroendocrine and Endocrine Tumor Translational Research Program (NET-VHIO), Vall Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Martínez-Badal+S%22">Martínez-Badal S</searchLink>; Neuroendocrine and Endocrine Tumor Translational Research Program (NET-VHIO), Vall Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Oncology Data Science Group (ODysSey), Vall d'Hebron Institute of Oncology, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Elguero+B%22">Elguero B</searchLink>; Neuroendocrine and Endocrine Tumor Translational Research Program (NET-VHIO), Vall Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Stem Cell and Cancer Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Capdevila+J%22">Capdevila J</searchLink>; Department of Medical Oncology, Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Neuroendocrine and Endocrine Tumor Translational Research Program (NET-VHIO), Vall Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2026 Mar 09; Vol. 16, pp. 1802225. <i>Date of Electronic Publication: </i>2026 Mar 09 (<i>Print Publication: </i>2026).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Case Reports; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41878530
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fonc.2026.1802225
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1802225
    Titles:
      – TitleFull: Case Report: Lorlatinib for the treatment of ALK-rearranged poorly differentiated thyroid carcinoma after progression to prior ALK-specific tyrosine-kinase inhibitor.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Yaringaño J
      – PersonEntity:
          Name:
            NameFull: Hernando J
      – PersonEntity:
          Name:
            NameFull: García-Álvarez A
      – PersonEntity:
          Name:
            NameFull: Iglesias-Felip C
      – PersonEntity:
          Name:
            NameFull: Zafón C
      – PersonEntity:
          Name:
            NameFull: Vivancos A
      – PersonEntity:
          Name:
            NameFull: Roca-Herrera M
      – PersonEntity:
          Name:
            NameFull: Pérez-Fernández S
      – PersonEntity:
          Name:
            NameFull: Martínez-Badal S
      – PersonEntity:
          Name:
            NameFull: Elguero B
      – PersonEntity:
          Name:
            NameFull: Capdevila J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 09
              M: 03
              Text: 2026 Mar 09
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 2234-943X
          Numbering:
            – Type: volume
              Value: 16
          Titles:
            – TitleFull: Frontiers in oncology
              Type: main
ResultId 1